Proteomics in animal models of Alzheimer's and Parkinson's diseases

Ageing Research Reviews

Volumn 8, Issue 1, 2009, Pages 1-17

  Sowell, Renã A ^a,b   Owen, Joshua B ^a,b   Allan Butterfield, D ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Animal models; Parkinson's disease; Proteomics

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; DJ 1 PROTEIN; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHOTRANSFERASE; PRESENILIN 1; PRESENILIN 2; PTEN INDUCED PUTATIVE KINASE 1; QUINONE DERIVATIVE; TAU PROTEIN; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; CAENORHABDITIS ELEGANS; DROSOPHILA; ELECTROSPRAY MASS SPECTROMETRY; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; LEWY BODY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MISSENSE MUTATION; NERVE FIBER TRANSECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENESCENCE; SENESCENCE ACCELERATED MOUSE; SENILE PLAQUE; SHORT SURVEY; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; TRANSGENIC RAT; WILD TYPE;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MUTATION; PARKINSON DISEASE; PROTEINS; PROTEOMICS;

ANIMALIA;

EID: 57749184790     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2008.07.003     Document Type: Short Survey

References (120)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., and Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 1 (2000) 239-252
2. Association AP. Diagnostic and Statistical Manual for Mental Disorders (2000), American Psychiatric Association, Washington, DC
3. Bajo M., Yoo B.C., Cairns N., Gratzer M., and Lubec G. Neurofilament proteins NF-L, NF-M and NF-H in brain of patients with Down syndrome and Alzheimer's disease. Amino Acids 21 3 (2001) 293-301
4. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 3 (1999) 1127-1137
5. Bird T.D., Lampe T.H., Nemens E.J., Miner G.W., Sumi S.M., and Schellenberg G.D. Familial Alzheimer's disease in American descendants of the Volga Germans: probable genetic founder effect. Ann. Neurol. 23 1 (1988) 25-31
6. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 5604 (2003) 256-259
7. Boyd-Kimball D., Poon H.F., Lynn B.C., Cai J., Pierce Jr. W.M., Klein J.B., Ferguson J., Link C.D., and Butterfield D.A. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiol. Aging 27 9 (2006) 1239-1249
8. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., and Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132 2 (2005) 313-324
9. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 4 (1991) 239-259
10. Brady S.T. Motor neurons and neurofilaments in sickness and in health. Cell 73 1 (1993) 1-3
11. Breslow J.L., Zannis V.I., SanGiacomo T.R., Third J.L., Tracy T., and Glueck C.J. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23 8 (1982) 1224-1235
12. Bulliard C., Zurbriggen R., Tornare J., Faty M., Dastoor Z., and Dreyer J.L. Purification of a dichlorophenol-indophenol oxidoreductase from rat and bovine synaptic membranes: tight complex association of a glyceraldehyde-3-phosphate dehydrogenase isoform, TOAD64, enolase-gamma and aldolase C. Biochem. J. 324 Pt 2 (1997) 555-563
13. Butterfield D.A. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 1000 1-2 (2004) 1-7
14. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 12 (2001) 548-554
15. Butterfield D.A., Gnjec A., Poon H.F., Castegna A., Pierce W.M., Klein J.B., and Martins R.N. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10 4 (2006) 391-397
16. Butterfield D.A., Hensley K., Cole P., Subramaniam R., Aksenov M., Aksenova M., Bummer P.M., Haley B.E., and Carney J.M. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J. Neurochem. 68 6 (1997) 2451-2457
17. Butterfield D.A., and Poon H.F. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp. Gerontol. 40 10 (2005) 774-783
18. Butterfield D.A., Reed T., Newman S.F., and Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43 5 (2007) 658-677
19. Casamenti F., Prosperi C., Scali C., Giovannelli L., Colivicchi M.A., Faussone-Pellegrini M.S., and Pepeu G. Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer's disease. Neuroscience 91 3 (1999) 831-842
20. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363 9415 (2004) 1139-1146
21. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I. Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33 4 (2002) 562-571
22. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II. Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82 6 (2002) 1524-1532
23. Chinta S.J., Rajagopalan S., Butterfield D.A., and Andersen J.K. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 402 1-2 (2006) 137-141
24. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 5123 (1993) 921-923
25. David D.C., Ittner L.M., Gehrig P., Nergenau D., Shepherd C., Halliday G., and Gotz J. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 6 24 (2006) 6566-6577
26. Dawson T.M., and Dawson V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 5 Suppl. (2002) 1058-1061
27. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 5646 (2003) 819-822
28. de Hostos E.L., Bradtke B., Lottspeich F., Guggenheim R., and Gerisch G. Coronin, an actin binding protein of Dictyostelium discoideum localized to cell surface projections, has sequence similarities to G protein beta subunits. EMBO J. 10 13 (1991) 4097-4104
29. De Iuliis A., Grigoletto J., Recchia A., Giusti P., and Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta 357 2 (2005) 202-209
30. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., and Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 11 Suppl. 5 (2000) S21-S23
31. Diedrich M., Mao L., Bernreuther C., Zabel C., Nebrich G., Kleene R., and Klose J. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics 8 6 (2008) 1266-1275
32. Dougherty M.K., and Morrison D.K. Unlocking the code of 14-3-3. J. Cell Sci. 117 Pt 10 (2004) 1875-1884
33. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., Butterfield D.A., and Morley J.E. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 84 5 (2003) 1173-1183
34. Farrer M., Stone J., Mata I.F., Lincoln S., Kachergus J., Hulihan M., Strain K.J., and Maraganore D.M. LRRK2 mutations in Parkinson disease. Neurology 65 5 (2005) 738-740
35. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
36. Flood J.F., and Morley J.E. Learning and memory in the SAMP8 mouse. Neurosci. Biobehav. Rev. 22 1 (1998) 1-20
37. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 6311 (1991) 704-706
38. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., and Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126 4 (2006) 775-788
39. Heikkila R.E., and Sonsalla P.K. The use of the MPTP-treated mouse as an animal model of parkinsonism. Can. J. Neurol. Sci. 14 3 Suppl. (1987) 436-440
40. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 5 (1995) 2146-2156
41. Hoffman P.N., Cleveland D.W., Griffin J.W., Landes P.W., Cowan N.J., and Price D.L. Neurofilament gene expression: a major determinant of axonal calibre. Proc. Natl. Acad. Sci. U.S.A. 84 10 (1987) 3472-3476
42. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 5284 (1996) 99-102
43. Hunot S., and Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S49-S58 (discussion S58-60)
44. Ichibangase T., Saimaru H., Takamura N., Kuwahara T., Koyama A., Iwatsubo T., and Imai K. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Biomed. Chromatogr. 22 3 (2008) 232-234
45. Ikegami S., Shumiya S., and Kawamura H. Age-related changes in radial-arm maze learning and basal forebrain cholinergic systems in senescence accelerated mice (SAM). Behav. Brain Res. 51 1 (1992) 15-22
46. Jin J., Meredith G.E., Chen L., Zhou Y., Xu J., Shie F.S., Lockhart P., and Zhang J. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res. 134 1 (2005) 119-138
47. Kagan V.E., Shvedova A., Serbinova E., Khan S., Swanson C., Powell R., and Packer L. Dihydrolipoic acid-a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Biochem. Pharmacol. 44 8 (1992) 1637-1649
48. Kaul S.C., Taira K., Pereira-Smith O.M., and Wadhwa R. Mortalin: present and prospective. Exp. Gerontol. 37 10-11 (2002) 1157-1164
49. Kekelidze T., Khait I., Togliatti A., Benzecry J.M., Wieringa B., and Holtzman D. Altered brain phosphocreatine and ATP regulation when mitochondrial creatine kinase is absent. J. Neurosci. Res. 66 5 (2001) 866-872
50. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 6676 (1998) 605-608
51. Klose J., and Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16 6 (1995) 1034-1059
52. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 2 (1998) 106-108
53. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 15 (1998) 1044-1053
54. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., and Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78 2 (2001) 413-416
55. Lees A.J. When did Ray Kennedy's Parkinson's disease begin?. Mov. Disord. 7 2 (1992) 110-116
56. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 6701 (1998) 451-452
57. Lesage S., Leutenegger A.L., Ibanez P., Janin S., Lohmann E., Durr A., and Brice A. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am. J. Hum. Genet. 77 2 (2005) 330-332
58. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 5226 (1995) 973-977
59. Lotharius J., and Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3 12 (2002) 932-942
60. Martin J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 340 25 (1999) 1970-1980
61. McLaughlin P., Zhou Y., Ma T., Liu J., Zhang W., Hong J.S., Kovacs M., and Zhang J. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53 6 (2006) 567-582
62. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., and Berg L. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 4 (1991) 479-486
63. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
64. Morley J.E., Farr S.A., and Flood J.F. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol. Learn. Mem. 78 1 (2002) 125-138
65. Nutt J.G., and Wooten G.F. Clinical practice. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353 10 (2005) 1021-1027
66. Ogawa N., Mizukawa K., Hirose Y., Kajita S., Ohara S., and Watanabe Y. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur. Neurol. 26 Suppl. 1 (1987) 16-23
67. Osorio C., Sullivan P.M., He D.N., Mace B.E., Ervin J.F., Strittmatter W.J., and Alzate O. Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol. Aging 28 12 (2007) 1853-1862
68. Ou P., Tritschler H.J., and Wolff S.P. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?. Biochem. Pharmacol. 50 1 (1995) 123-126
69. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 4 (2004) 595-600
70. Paolini M., Sapone A., and Gonzalez F.J. Parkinson's disease, pesticides and individual vulnerability. Trends Pharmacol. Sci. 25 3 (2004) 124-129
71. Papassotiropoulos A., Fountoulakis M., Dunckley T., Stephan D.A., and Reiman E.M. Genetics, transcriptomics, and proteomics of Alzheimer's disease. J. Clin. Psychiatry 67 4 (2006) 652-670
72. Periquet M., Corti O., Jacquier S., and Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic function. J. Neurochem. 95 5 (2005) 1259-1276
73. Perkins D.N., Pappin D.J., Creasy D.M., and Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20 18 (1999) 3551-3567
74. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 5321 (1997) 2045-2047
75. Poon H.F., Castegna A., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., Klein J.B., and Butterfield D.A. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience 126 4 (2004) 915-926
76. Poon H.F., Farr S.A., Banks W.A., Pierce W.M., Klein J.B., Morley J.E., and Butterfield D.A. Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. Brain Res. Mol. Brain Res. 138 1 (2005) 8-16
77. Poon H.F., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., Klein J.B., and Butterfield D.A. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem. Int. 46 2 (2005) 159-168
78. Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., and Butterfield D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol. Dis. 18 3 (2005) 492-498
79. Poon H.F., Joshi G., Sultana R., Farr S.A., Banks W.A., Morley J.E., Calabrese V., and Butterfield D.A. Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 1018 1 (2004) 86-96
80. Putkey J.A., Kleerekoper Q., Gaertner T.R., and Waxham M.N. A new role for IQ motif proteins in regulating calmodulin function. J. Biol. Chem. 278 50 (2003) 49667-49670
81. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2 1 (2002) 3-10
82. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., and Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J. 18 6 (2004) 617-626
83. Reed T., Perluigi M., Sultana R., Pierce W.M., Klein J.B., Turner D.M., Coccia R., Markesbery W.R., and Butterfield D.A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30 1 (2008) 107-120
84. Reisberg B., Ferris S.H., Shulman E., Steinberg G., Buttinger C., Sinaiko E., Borenstein J., de Leon M.J., and Cohen J. Longitudinal course of normal aging and progressive dementia of the Alzheimer's type: a prospective study of 106 subjects over a 3.6 year mean interval. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 3-5 (1986) 571-578
85. Rite I., Arguelles S., Venero J.L., Garcia-Rodriguez S., Ayala A., Cano J., and Machado A. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res. 85 16 (2007) 3607-3618
86. Rocchi A., Pellegrini S., Siciliano G., and Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res. Bull. 61 1 (2003) 1-24
87. Sarafian T.A., Verity M.A., Vinters H.V., Shih C.C., Shi L., Ji X.D., Dong L., and Shau H. Differential expression of peroxiredoxin subtypes in human brain cell types. J. Neurosci. Res. 56 2 (1999) 206-212
88. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 7 (2006) 1744-1754
89. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 8 (1996) 864-870
90. Schonberger S.J., Edgar P.F., Kydd R., Faull R.L., and Cooper G.J. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1 12 (2001) 1519-1528
91. Sen C.K., Roy S., Han D., and Packer L. Regulation of cellular thiols in human lymphocytes by alpha-lipoic acid: a flow cytometric analysis. Free Radic. Biol. Med. 22 7 (1997) 1241-1257
92. Serot J.M., Christmann D., Dubost T., and Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 63 4 (1997) 506-508
93. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 6534 (1995) 754-760
94. Shin S.J., Lee S.E., Boo J.H., Kim M., Yoon Y.D., Kim S.I., and Mook-Jung I. Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics 4 11 (2004) 3359-3368
95. Sizova D., Charbaut E., Delalande F., Poirier F., High A.A., Parker F., Van Dorsselaer A., Duchesne M., and Diu-Hercend A. Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol. Aging 28 3 (2007) 357-370
96. Skold K., Svensson M., Nilsson A., Zhang X., Nydahl K., Caprioli R.M., Svenningsson P., and Andren P.E. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J. Proteome Res. 5 2 (2006) 262-269
97. Smolka M.B., Zhou H., Purkayastha S., and Aebersold R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal. Biochem. 297 1 (2001) 25-31
98. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., and Nicholson G.A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49 3 (2001) 313-319
99. Strittmatter W.J., and Roses A.D. Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19 (1996) 53-77
100. Tilleman K., Stevens I., Spittaels K., Haute C.V., Clerens S., Van Den Bergh G., Geerts H., Van Leuven F., Vandesande F., and Moens L. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics 2 1 (2002) 94-104
101. Tonge R., Shaw J., Middleton B., Rowlinson R., Rayner S., Young J., Pognan F., Hawkins E., Currie I., and Davison M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 1 3 (2001) 377-396
102. Tsuji T., Shiozaki A., Kohno R., Yoshizato K., and Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 27 10 (2002) 1245-1253
103. Valastro B., Dekundy A., Krogh M., Lundblad M., James P., Danysz W., Quack G., and Cenci M.A. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J. Neurochem. 102 4 (2007) 1395-1409
104. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 5674 (2004) 1158-1160
105. Van Laar V.S., Dukes A.A., Cascio M., and Hastings T.G. Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol. Dis. 29 3 (2008) 477-489
106. Venero J.L., Revuelta M., Cano J., and Machado A. Time course changes in the dopaminergic nigrostriatal system following transection of the medial forebrain bundle: detection of oxidatively modified proteins in substantia nigra. J. Neurochem. 68 6 (1997) 2458-2468
107. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 2 (2000) 721-729
108. von Coelln R., Dawson V.L., and Dawson T.M. Parkin-associated Parkinson's disease. Cell Tissue Res. 318 1 (2004) 175-184
109. Wadhwa R., Takano S., Kaur K., Aida S., Yaguchi T., Kaul Z., Hirano T., Taira K., and Kaul S.C. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem. J. 391 Pt 2 (2005) 185-190
110. Wilson K.E., Marouga R., Prime J.E., Pashby D.P., Orange P.R., Crosier S., Keith A.B., Lathe R., Mullins J., Estibeiro P., Bergling H., Hawkins E., and Morris C.M. Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. Proteomics 5 15 (2005) 3851-3858
111. Wolters D.A., Washburn M.P., and Yates III J.R. An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 73 23 (2001) 5683-5690
112. Wood D.R., Nye J.S., Lamb N.J., Fernandez A., and Kitzmann M. Intracellular retention of caveolin 1 in presenilin-deficient cells. J. Biol. Chem. 280 8 (2005) 6663-6668
113. Wu J.T., Lin H.C., Hu Y.C., and Chien C.T. Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nat. Cell Biol. 7 10 (2005) 1014-1020
114. Xun Z., Sowell R.A., Kaufman T.C., and Clemmer D.E. Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease. J. Proteome Res. 6 9 (2007) 3729-3738
115. Xun Z., Sowell R.A., Kaufman T.C., and Clemmer D.E. Protein expression in a Drosophila model of Parkinson's disease. J. Proteome Res. 6 1 (2007) 348-357
116. Xun Z., Sowell R.A., Kaufman T.C., and Clemmer D.E. Quantitative proteomics of a presymptomatic A53T a-synuclein drosophila model of Parkinson's disease. Mol. Cell Proteomics (2008)
117. Zabel C., Andreew A., Mao L., and Hartl D. Protein expression overlap: more important than which proteins change in expression?. Expert Rev. Proteomics 5 2 (2008) 187-205
118. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 2 (2004) 164-173
119. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97 24 (2000) 13354-13359
120. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 4 (2004) 601-607